Bastard, PaulGut, MartaCasanova, Jean-Laurent2022-07-082022-07-082020Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020 Oct 23; 370(6515): eabd4585. DOI: 10.1126/science.abd45850036-8075http://hdl.handle.net/10230/53698Interindividual clinical variability in the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is vast. We report that at least 101 of 987 patients with life-threatening coronavirus disease 2019 (COVID-19) pneumonia had neutralizing immunoglobulin G (IgG) autoantibodies (auto-Abs) against interferon-ω (IFN-ω) (13 patients), against the 13 types of IFN-α (36), or against both (52) at the onset of critical disease; a few also had auto-Abs against the other three type I IFNs. The auto-Abs neutralize the ability of the corresponding type I IFNs to block SARS-CoV-2 infection in vitro. These auto-Abs were not found in 663 individuals with asymptomatic or mild SARS-CoV-2 infection and were present in only 4 of 1227 healthy individuals. Patients with auto-Abs were aged 25 to 87 years and 95 of the 101 were men. A B cell autoimmune phenocopy of inborn errors of type I IFN immunity accounts for life-threatening COVID-19 pneumonia in at least 2.6% of women and 12.5% of men.application/pdfengThis is an open-access article distributed under the terms of the Creative Commons Attribution license http://creativecommons.org/licenses/by/4.0/, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Antibodies, NeutralizingCOVID-19Asymptomatic InfectionsBetacoronavirusCoronavirus InfectionsInterferon Type Iinfo:eu-repo/semantics/articlehttp://dx.doi.org/10.1126/science.abd4585info:eu-repo/semantics/openAccess